Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from United Therapeutics ( (UTHR) ).
On April 25, 2025, United Therapeutics Corporation entered into a Credit Agreement with Wells Fargo and other lenders, establishing an unsecured revolving credit facility of up to $2.5 billion, with the possibility of increasing by an additional $750 million. The agreement allows for refinancing existing debt and supporting general corporate purposes. Concurrently, the company borrowed $200 million to repay its previous 2022 Credit Agreement, which was terminated without penalties.
Spark’s Take on UTHR Stock
According to Spark, TipRanks’ AI Analyst, UTHR is a Outperform.
United Therapeutics’ overall score reflects its strong financial performance and positive outlook from the earnings call. The company benefits from robust revenue growth and strategic advancements in clinical trials. Despite technical indicators suggesting neutral momentum, the stock’s valuation remains attractive. The sequential decline in Q4 net revenue is a minor concern but is outweighed by the company’s long-term growth prospects.
To see Spark’s full report on UTHR stock, click here.
More about United Therapeutics
United Therapeutics Corporation operates in the biotechnology industry, focusing on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.
YTD Price Performance: -19.11%
Average Trading Volume: 499,438
Technical Sentiment Signal: Sell
Current Market Cap: $13.09B
See more data about UTHR stock on TipRanks’ Stock Analysis page.